Polyamine analogues as therapeutic and diagnostic agents
Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.
1. A N 1 -monosubstituted polyamine analogue or derivative represented by the formula
R—CO—NH—(CH 2 ) 3 —NH—(CH 2 ) 4 —NH—(CH 2 ) 3 —NH 2
wherein R is selected from a D or L amino acid; D or L ornithine, an alicyclic, a single or multi-ring aromatic; aliphatic-substituted single or multi-ring aromatic; and a substituted or unsubstituted, single or multi-ring heterocyclic and wherein when R is a substituted single or multi-ring heterocyclic, heterocyclic is substituted with at least one member of the group consisting of: OH, halogen, NO 2 , NH 2 , NH(CH 2 ) n CH 3 , N((CH 2 ) n CH 3 ) 2 , CN, (CH 2 ) n CH 3 , O(CH 2 ) n CH 3 , S(CH 2 ) n CH 3 , NHCO(CH 2 ) n CH 3 , O(CF 2 ) n CF 3 , COO(CH 2 ) n CH 3 , wherein n is 0–10 and
wherein said analogue or derivative does not have a formula represented by ID 1022, 1043, or 1202.
2. An analogue or derivative according to claim 1 wherein R is a D or L amino acid or D or L ornithine.
3. A composition comprising a polyamine analogue or derivative according to claim 1 or 2 and a pharmaceutically acceptable excipient.
4. A composition comprising a polyamine analogue or derivative according to claim 1 , a pharmaceutically acceptable excipient, and an inhibitor of polyamine synthesis.
5. A composition according to claim 4 herein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).
6. A method for treating a disease or a condition in a subject associated with undesired cell proliferation and/or which is treatable by inhibition of polyamine transport, comprising administering to said subject a polyamine analogue or derivative according to claim 1 .
7. A method according to claim 6 wherein said undesired cell proliferation is associated with proliferation of cells of the immune system, cells of the vascular neontima, tumor cells or with undesired angiogenesis.
8. A method according to claim 6 wherein said disease or condition is cancer or post-angioplasty injury.
9. A method according to claim 6 further comprising administration of an inhibitor of polyamine synthesis.
10. A method according to claim 9 wherein said inhibitor of polyamine systhesis is difluoromethylornithine (DFMO).
11. A composition according to claim 4 or 5 in solid form.
12. A composition according to claim 4 or 5 in liquid form.
13. A method according to any one of claims 6 –10 wherein said administering is performed orally, parenterally, topically, transdermally, intravaginally, intranasally, intrabronchially, intracranially, intraocularly, intraaurally, or rectally, or by injection.
14. A method according to claim 13 wherein said administering by injection is intravenous, subcutaneous, intramuscular, intracranial, or intraperitoneal.
15. The analogue or derivative of claim 1 , wherein said substituted or unsubstituted heterocyclic is a pyrrolidine or a substituted pyrrolidine.
16. The analogue or derivative of claim 15 , wherein said substituted pyrrolidine is a N-substituted pyrrolidine.
17. The analogue or derivative of claim 16 represented by the formula ID 1158.
18. The analogue or derivative of claim 1 represented by the formula ID 1224.
19. A method according to claim 6 wherein said condition is associated with cancer.